Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib/II Trial Evaluating the Safety, Tolerability and Immunological Activity of Durvalumab (MEDI4736) (Anti-PD-L1) Plus Tremelimumab (Anti-CTLA-4) Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Next Previous
Trial Profile

Phase Ib/II Trial Evaluating the Safety, Tolerability and Immunological Activity of Durvalumab (MEDI4736) (Anti-PD-L1) Plus Tremelimumab (Anti-CTLA-4) Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MEDITREME

Most Recent Events

  • 10 Apr 2024 Primary endpoint (3 months and 6 months progression-free survival (PFS) rate) of 3-month PFS in MSS patients has been met.
  • 10 Apr 2024 Results assessing combination of durvalumab-tremelimumab with mFOLFOX6 in RAS-mutated metastatic colorectal cancer, presented at the 115th Annual Meeting of the American Association for Cancer Research
  • 23 Sep 2023 Results assessing the immune response observed following immune monitoring of patients before and during MEDITREME trial, presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top